Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Jul 1, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients with advanced pancreatic cancer, specifically a subtype known as basal-like pancreatic adenocarcinoma. Researchers want to find the safest and most effective dose of a combination of three drugs: gemcitabine, erlotinib, and nab-paclitaxel. The study will also examine how well this treatment works in patients with this specific type of cancer compared to standard treatments. Participants will undergo a test to confirm their cancer subtype and will be monitored for safety and how well they respond to the treatment.

To be eligible for this trial, participants need to be at least 18 years old, provide consent to join, and have a good overall health status. They should also be willing to undergo a tissue biopsy if necessary. However, individuals with certain conditions, such as those who have had previous treatments for pancreatic cancer or have recently diagnosed brain metastasis, may not qualify. If you or a loved one are considering this trial, you can expect to receive close monitoring and support throughout the study as researchers gather important information to improve treatment for pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information. Subjects is willing and able to comply with study procedures based on the judgment of the investigator.
• • Age ≥ 18 years at the time of consent.
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
• • The subject must consent to a mandatory pre-study biopsy if archival tissue is not available or sufficient.
• • Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• Exclusion Criteria:
• • Disease is not measurable according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1
• • Not having histological or cytological evidence/confirmation of metastatic pancreatic adenocarcinoma.
• • Prior pancreatic-focused therapy.
• • Brain metastasis diagnosed within the last 4 weeks.